Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MyoKardia Inc. MYOK

Healthcare Biotechnology
"MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac... see more

Recent & Breaking News (NDAQ:MYOK)

MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe

GlobeNewswire October 25, 2018

MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy

GlobeNewswire October 24, 2018

MyoKardia to Host R&D Day on October 30, 2018

GlobeNewswire October 22, 2018

MyoKardia to Present at the 2018 Cantor Global Healthcare Conference

GlobeNewswire September 24, 2018

MyoKardia to Present at Two Upcoming Investor Conferences in September

GlobeNewswire August 29, 2018

New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation

GlobeNewswire August 23, 2018

Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire August 21, 2018

MyoKardia Reports Second Quarter 2018 Financial Results

GlobeNewswire August 8, 2018

MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference

GlobeNewswire August 7, 2018

MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018

GlobeNewswire August 1, 2018

MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire June 26, 2018

Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire June 6, 2018

MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

GlobeNewswire May 10, 2018

MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire May 10, 2018

MyoKardia Reports First Quarter 2018 Financial Results

GlobeNewswire May 8, 2018

MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018

GlobeNewswire May 3, 2018

MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer

GlobeNewswire April 4, 2018

MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients

GlobeNewswire April 2, 2018

Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire March 16, 2018

MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results

GlobeNewswire March 8, 2018